Cerus (CERS) Earnings per Share (Diluted)

: $-0.21 (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Cerus's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.21.

Cerus's EPS (Basic) for the three months ended in Dec. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.21.

Cerus's EPS without NRI for the three months ended in Dec. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.19.

During the past 3 years, the average EPS without NRIGrowth Rate was 7.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 16.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.10% per year.

During the past 13 years, Cerus's highest 3-Year average EPS without NRI Growth Rate was 31.00% per year. The lowest was -23.90% per year. And the median was 5.90% per year.

Cerus Earnings per Share (Diluted) Historical Data

The historical data trend for Cerus's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

-0.51

-0.24

-0.32

-0.24

-0.21

Cerus Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)																-0.08	-0.09	-0.07	-0.04	-0.01

Competitive Comparison

For the Medical Devices subindustry, Cerus's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerus PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's PE Ratio falls into.

Cerus Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Cerus's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-37.489	-	0)	/	180.270
	=	-0.21

Cerus's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-1.328	-	0)	/	181.230
	=	-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Cerus (NAS:CERS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cerus Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Cerus's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerus (CERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

CU2:Germany

Address

1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520

Website

http://www.cerus.com

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Executives

Eric Bjerkholt	director	132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena	director	C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze	director	3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash	director	C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman	officer: President, Cerus Europe	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard	officer: Chief Legal Officer	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green	officer: Chief Accounting Officer	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin	officer: Chief Medical Officer	15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman	officer: Chief Commercial Officer	3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan	director	C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore	officer: SR. V.P. Regulatory, Clinical	C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451